HIV-1 drug resistance (HIVDR) genotyping is an essential component of the WHO global HIVDR surveillance strategy. Plasma “gold standard” specimen type for HIVDR genotyping, but its use may not be feasible in rural, remote areas in low- and middle-income countries, since preparing and storing it ...require personnel and laboratory infrastructure that are often lacking. An alternative specimen type is dried blood spots (DBS), which can be made without special laboratory processing. DBS are more easily transported than plasma because they can be shipped at ambient temperature as non-hazardous materials using regular mail or courier services.
3rd edition
more
The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable ...results at the national, regional and global levels.
This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years.
more
CDC leads an international surveillance effort to estimate the occurrence of HIV drug resistance among people with HIV who are taking dolutegravir (DTG)-based treatments. This surveillance effort utilizes Cyclical Acquired HIV Drug Resistance Surveillance (CADRE), a laboratory-based HIV drug resista...nce monitoring process.
more
Results of the first national survey, 2013–2014
Tuberculosis MDR-TB & XDR-TB The 2008 Report
Int J Tuberc Lung Dis. 2019 Jul 1;23(7):858–864.Namibia ranks among the 30 high TB burden countries worldwide. Here, we report results of the second nationwide anti-TB drug resistance survey. To assess the prevalence and trends of multidrug-resistant TB (MDR-TB) in Namibia.
From 2014 to 2015, pat...ients with presumptive TB in all regions of Namibia had sputum subjected to mycobacterial culture and phenotypic drug susceptibility testing (DST) for rifampicin, isoniazid, ethambutol and streptomycin if positive on smear microscopy and/or Xpert MTB/RIF.
more
Launch of the WHO Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Key findings
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex F
Topics in Antiviral Medicine, March 4, 2025
During ARV drug pressure the HIV-1 RT is able to develop resistance to these drugs by generating mutations
Training materials for healthcare workers
In November 2022, WHO launched a strategy to address antimalarial drug resistance in Africa, emphasizing the need for stronger surveillance. While regional monitoring networks have been active in other regions, most in Africa have not convened since 2017–2018. To renew collaboration, WHO organized... a meeting bringing together countries from the African and Eastern Mediterranean regions. Participants shared recent data on antimalarial efficacy and resistance. While artemisinin-based combination therapies remain highly effective, some sites in Uganda and the United Republic of Tanzania reported lower-than-expected efficacy of artemether–lumefantrine. Delayed parasite clearance linked to Plasmodium falciparum Kelch-13 mutations was noted in Eritrea, Rwanda, Uganda and the United Republic of Tanzania. Discussions highlighted challenges in therapeutic efficacy studies, molecular marker surveillance and the need for improved genotyping to distinguish relapses from new infections.
more